Wall Street Zen Downgrades Karyopharm Therapeutics (NASDAQ:KPTI) to Sell

Karyopharm Therapeutics (NASDAQ:KPTI) was downgraded by equities research analysts at Wall Street Zen from a “hold” rating to a “sell” rating in a research note issued on Saturday.

KPTI has been the subject of several other research reports. Robert W. Baird downgraded Karyopharm Therapeutics from an “outperform” rating to a “neutral” rating and set a $3.00 target price for the company. in a research note on Friday, July 31st. HC Wainwright downgraded shares of Karyopharm Therapeutics from a “buy” rating to a “negative” rating in a research note on Friday, July 31st. Piper Sandler decreased their price target on shares of Karyopharm Therapeutics to $7.00 and set an “overweight” rating on the stock in a report on Friday, July 31st. Weiss Ratings upgraded shares of Karyopharm Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Thursday. Finally, Royal Bank Of Canada restated an “outperform” rating and issued a $16.00 target price on shares of Karyopharm Therapeutics in a research report on Tuesday, July 21st. One equities research analyst has rated the stock with a Strong Buy rating, three have given a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $11.50.

Karyopharm Therapeutics Stock Performance

Karyopharm Therapeutics stock opened at $2.02 on Friday. Karyopharm Therapeutics has a 52 week low of $1.80 and a 52 week high of $10.99. The stock has a market capitalization of $45.81 million, a P/E ratio of -0.15 and a beta of 0.90. The stock has a fifty day moving average of $7.47 and a 200-day moving average of $7.86.

Karyopharm Therapeutics (NASDAQ:KPTI) last announced its quarterly earnings data on Thursday, August 13th. The company reported ($2.32) earnings per share for the quarter, missing the consensus estimate of ($1.37) by ($0.95). The company had revenue of $33.43 million during the quarter, compared to analyst estimates of $32.19 million. On average, research analysts forecast that Karyopharm Therapeutics will post -4.28 earnings per share for the current year.

Institutional Trading of Karyopharm Therapeutics

A number of hedge funds have recently made changes to their positions in the company. Bank of New York Mellon Corp bought a new stake in shares of Karyopharm Therapeutics during the second quarter worth about $559,000. Avidity Partners Management LP raised its holdings in Karyopharm Therapeutics by 244.6% in the 1st quarter. Avidity Partners Management LP now owns 463,741 shares of the company’s stock valued at $2,583,000 after buying an additional 329,175 shares during the last quarter. Royal Bank of Canada raised its holdings in Karyopharm Therapeutics by 4.1% in the 1st quarter. Royal Bank of Canada now owns 60,399 shares of the company’s stock valued at $336,000 after buying an additional 2,399 shares during the last quarter. Commodore Capital LP bought a new position in Karyopharm Therapeutics in the 1st quarter valued at approximately $10,862,000. Finally, OMERS ADMINISTRATION Corp acquired a new stake in Karyopharm Therapeutics during the 1st quarter worth approximately $108,000. 66.44% of the stock is owned by institutional investors and hedge funds.

About Karyopharm Therapeutics

Karyopharm Therapeutics (NASDAQ: KPTI) is a clinical-stage biopharmaceutical company focused on discovering and developing novel first-in-class drugs that target the nuclear export protein XPO1. The company’s lead product, selinexor (marketed as XPOVIO), is an oral selective inhibitor of nuclear export (SINE) compound approved for treatment of multiple myeloma and diffuse large B-cell lymphoma. In addition to selinexor, Karyopharm’s pipeline includes second-generation SINE compounds and combination studies in solid tumors and hematologic malignancies.

Founded in 2008 and headquartered in Newton, Massachusetts, Karyopharm has built a research platform around modulation of nuclear export pathways.